Valentina Restelli1, Monica Lupi1, Micaela Vagni1, Rosaria Chilà1, Francesco Bertoni2,3, Giovanna Damia4, Laura Carrassa5. 1. Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri" (IRFMN), via La Masa 19, 20156, Milan, Italy. 2. Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona, Switzerland. 3. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland. 4. Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri" (IRFMN), via La Masa 19, 20156, Milan, Italy. giovanna.damia@marionegri.it. 5. Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri" (IRFMN), via La Masa 19, 20156, Milan, Italy. laura.carrassa@marionegri.it.
Abstract
BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with an unfavorable clinical course. Besides deregulation of the cell cycle, B cell receptor (BCR) signaling, essential for MCL proliferation and survival, is also often deregulated due to constitutive activation of Bruton's tyrosine kinase (BTK). The BTK inhibitor ibrutinib has been approved as a therapy for refractory MCL, and while it shows some clinical activity, patients frequently develop primary or secondary ibrutinib resistance and have very poor outcomes after relapsing following ibrutinib treatment. OBJECTIVE: To overcome ibrutinib resistance, new therapeutic approaches are needed. As checkpoint kinase 1 (Chk1) inhibitors have recently been shown to be effective as single agents in MCL, we assessed the combination of ibrutinib with Chk1 inhibitors. METHODS: We examined the activity of ibrutinib combined with the Chk1 inhibitor PF-00477736 in eight MCL cell lines and analyzed underlying cellular and molecular effects. RESULTS: The combination was synergistic in all tested cell lines through different mechanisms. The treatment induced apoptosis in ibrutinib-sensitive cell lines, while in ibrutinib-resistant cells the effect was mainly cytostatic and occurred at micromolar concentrations of ibrutinib. CONCLUSIONS: The pharmacological approach of simultaneously targeting cell cycle checkpoints (by Chk1 inhibitors) and pro-survival pathways (by ibrutinib) might offer a promising new therapeutic strategy for MCL patients.
BACKGROUND:Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with an unfavorable clinical course. Besides deregulation of the cell cycle, B cell receptor (BCR) signaling, essential for MCL proliferation and survival, is also often deregulated due to constitutive activation of Bruton's tyrosine kinase (BTK). The BTK inhibitor ibrutinib has been approved as a therapy for refractory MCL, and while it shows some clinical activity, patients frequently develop primary or secondary ibrutinib resistance and have very poor outcomes after relapsing following ibrutinib treatment. OBJECTIVE: To overcome ibrutinib resistance, new therapeutic approaches are needed. As checkpoint kinase 1 (Chk1) inhibitors have recently been shown to be effective as single agents in MCL, we assessed the combination of ibrutinib with Chk1 inhibitors. METHODS: We examined the activity of ibrutinib combined with the Chk1 inhibitor PF-00477736 in eight MCL cell lines and analyzed underlying cellular and molecular effects. RESULTS: The combination was synergistic in all tested cell lines through different mechanisms. The treatment induced apoptosis in ibrutinib-sensitive cell lines, while in ibrutinib-resistant cells the effect was mainly cytostatic and occurred at micromolar concentrations of ibrutinib. CONCLUSIONS: The pharmacological approach of simultaneously targeting cell cycle checkpoints (by Chk1 inhibitors) and pro-survival pathways (by ibrutinib) might offer a promising new therapeutic strategy for MCL patients.
Authors: Eleonora Marostica; Juthamas Sukbuntherng; David Loury; Jan de Jong; Xavier Woot de Trixhe; An Vermeulen; Giuseppe De Nicolao; Susan O'Brien; John C Byrd; Ranjana Advani; Jesse McGreivy; Italo Poggesi Journal: Cancer Chemother Pharmacol Date: 2014-11-08 Impact factor: 3.333
Authors: David Chiron; Maurizio Di Liberto; Peter Martin; Xiangao Huang; Jeff Sharman; Pedro Blecua; Susan Mathew; Priyanka Vijay; Ken Eng; Siraj Ali; Amy Johnson; Betty Chang; Scott Ely; Olivier Elemento; Christopher E Mason; John P Leonard; Selina Chen-Kiang Journal: Cancer Discov Date: 2014-07-31 Impact factor: 39.397
Authors: Nakhle S Saba; Delong Liu; Sarah E M Herman; Chingiz Underbayev; Xin Tian; David Behrend; Marc A Weniger; Martin Skarzynski; Jennifer Gyamfi; Lorena Fontan; Ari Melnick; Cliona Grant; Mark Roschewski; Alba Navarro; Sílvia Beà; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Adrian Wiestner Journal: Blood Date: 2016-04-28 Impact factor: 22.113
Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245